R&D channel feed – Endpoints News

R&D channel feed

Floundering in the wake of an FDA approval, Achaogen makes a second round of deep cuts to stay alive

7 years ago

In another try at lung cancer niche, J&J nabs a potential Tagrisso rival for $50M-plus

7 years ago

Eli Lilly touts MACE win for diabetes blockbuster Trulicity — a 'nice positive'

7 years ago

Novartis CEO Vas Narasimhan lines up his late-stage blockbuster contenders — mixing old favorites and add-ons

7 years ago

Clearside Bio loses nearly half its value pre-market as lead eye drug fails pivotal test

7 years ago

Tripped up by the FDA, Novartis says it is dropping out of the US race to win an OK for a blockbuster Rituxan rival

7 years ago

Experts question Amarin's early touting of Vascepa data ahead of detailed results

7 years ago

Urovant's overactive bladder drug scores in mid-stage trial

7 years ago

Climbing the blockbuster mountain, Roche/AbbVie team heralds a win in frontline CLL PhIII

7 years ago

As rivals press in, Stanford spinout Forty Seven burnishes its prospects from an impressive PhIb

7 years ago

GSK tosses a trio of clinical-stage drugs on trial failures, winnowing out its respiratory pipeline as cancer moves to center stage

7 years ago

Acadia says Nuplazid cleared main goal in depression study, but data appear mixed

7 years ago

The next big thing at GlaxoSmithKline R&D is clearly oncology — respiratory can take a back seat now

7 years ago

Novartis has scrapped a fifth of its programs in pursuit of 'truly impactful' drugs, Bradner reveals

7 years ago

Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab

7 years ago

Pfizer, Novartis tie up to target NASH in crowded field

7 years ago

Esperion’s cholesterol drug clears the last big safety hurdle, turning the corner to the FDA — now the big challenge looms

7 years ago

Ultragenyx stumbles with UX007 PhIII, shares plunge

7 years ago

Constipation drug maker Synergy looks to renegotiate bloated loan agreement — shares tumble

7 years ago

Deborah Dunsire kicks off her new gig as Lundbeck CEO with a key PhIII trial failure

7 years ago

Biogen, Eisai fight back against accusations their big BAN2401 study was skewed -- but this fight isn't over yet

7 years ago

Mixed data doesn't stop this biotech unicorn from plotting a looming PhIII showdown

7 years ago

Bayer, Orion prostate cancer drug delays spread of disease in PhIII, but can it make a mark in a crowded market?

7 years ago

Fresh from a $72M raise, Jeff Aronin's new lead rare disease drug is flagged as a failure

7 years ago

First page Previous page 260 261 262263264 265 266 Next page Last page